SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Oncology Pharmacy Practice
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by de Lemos, M. L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Lemos, M. L
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Vinorelbine and venous irritation: optimal parenteral administration

Mário L de Lemos, M.Sc. (Clin Pharm), PharmD

Provincial Systemic Therapy Program, British Columbia Cancer Agency, Vancouver, B.C., Canada

Vinorelbine is a vesicant associated with extra-vasation hazards and injection site reactions, which can be alleviated by shortening of infusion time and flushing of intravenous fluid. A critical review of the current evidence showed that the optimal administration is to flush ≥75-124 mL of intravenous fluid after vinorelbine infusion. In travenous push administration over 1-2 min does not seem to offer significant improvement over rapid intravenous infusion over 6-10 min.

Key Words: intravenous infusions • vascular diseases • vinorelbine

Journal of Oncology Pharmacy Practice, Vol. 11, No. 2, 79-81 (2005)
DOI: 10.1191/1078155205jp146oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Oncol Pharm PractHome page
V. Wilmott, M. Humphries, and S. Grozdanov
Letter to the editor
Journal of Oncology Pharmacy Practice, June 1, 2006; 12(2): 123 - 123.
[PDF]


Advertisement